Ablynx extends R&D pact with Novartis

Belgium's Ablynx says it has agreed to extend its research collaboration with Novartis for another year. The two are exploring nanobodies, which are smaller than antibodies but easier to use. Novartis has the commercial rights to nanobody products developed in the partnership. Financial details were not disclosed. Release